SJShan Jiang

Shan Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shan Jiang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Different phenotypic presentations of congenital insensitivity to pain with anhidrosis in siblings with identical NTRK1 mutations: a case report and literature review

    by Liang Zhao, Meng Wang, Xiaoyan Peng, Jiaoping Wan, Naming Wu, Shan Jiang

    Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive disorder mainly caused by mutations in the NTRK1 gene. Its cardinal features include insensitivity to pain, anhidrosis, recurrent fever, and self-mutilating behavior. While CIPA siblings predominantly show similar phenotypes or severity differences positively correlated with age, phenotypic divergences that are age-independent, inversely correlated with age, or affect distinct organ systems have been rarely reported in siblings with identical NTRK1 mutations. We report two Han Chinese males, aged 29 and 16 years, who carried identical compound heterozygous NTRK1 mutations (c.446_447insTCTG, p. P149fs from the father and c.2293C>T, p. R765C from the mother) but exhibited markedly different clinical manifestations: the elder brother presented with chronic elbow ulcer, severe nail damage, and partial preservation of lingual temperature sensation with mild intellectual disability, whereas the younger brother had recurrent painless fractures, severe knee joint destruction, inability to stand independently, and severe intellectual disability with relatively mild skin and soft tissue involvement. A structured literature review identified 27 CIPA sibling families, among which phenotypic differences mostly manifested as age-positive severity or age-independent phenotypes. In contrast, our siblings exhibited a rare age-inverse divergence across distinct organ systems under an identical genotype. The elder brother was predominantly affected by skin and soft tissue, whereas the younger brother suffered from severe skeletal complications. This phenotypic divergence is unlikely to be fully explained by age or cumulative injury alone. These findings highlight this unexpected age-inverse phenotypic divergence among siblings with identical NTRK1 genotype, emphasizing the need for independent, comprehensive multi-organ assessments for each CIPA patient rather than predicting disease patterns in siblings solely based on the proband’s phenotype.

  • Open Access

    AGR2 promotes tumor progression by regulating macrophage polarization via the CD98hc-xCT/p-ERK pathway

    by Naming Wu, Liang Zhao, Shan Jiang

    Introduction: Anterior gradient 2 (AGR2) contributes to tumorigenesis, yet its function within the tumor microenvironment (TME) and in macrophage polarization remains unclear. This study assessed the prognostic significance of AGR2 and investigated its mechanism in cancer progression. Methods: We used TCGA for pan-cancer AGR2 expression and survival analysis, examined macrophage infiltration in clinical specimens, and performed in vitro experiments with recombinant AGR2 (rAGR2) to assess macrophage polarization. We verified AGR2’s interaction with the CD98hc-xCT receptor complex and explored related mechanisms via CD98hc knockdown. In vivo experiments were conducted in B16-F10 melanoma and Lewis lung carcinoma (LLC) models using flow cytometry. Results: Pan−cancer analyses showed that elevated AGR2 expression correlates with poor prognosis in multiple cancers and is associated with reduced immune infiltration. AGR2 is predominantly expressed in CD163+ M2−like tumor−associated macrophages (TAMs), with levels rising alongside tumor stage. In vitro, rAGR2 promoted M2 polarization while inhibiting M1 polarization of macrophages, and enhanced the pro−tumorigenic effects of M2−conditioned medium on cancer cell motility and proliferation. Mechanistically, AGR2 binds to the CD98hc−xCT receptor complex, activating the ERK pathway, an effect abrogated by CD98hc knockdown. In vivo, rAGR2 accelerated tumor growth in melanoma and lung cancer models, accompanied by increased TAM accumulation, a shift toward M2 polarization, and suppressed T-cell function. Discussion: AGR2 drives tumor progression by reprogramming TAMs toward an M2 phenotype and attenuating T−cell function via the CD98hc−xCT/p-ERK pathway, highlighting its potential as both a prognostic marker and a therapeutic target.

  • Open Access

    Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells

    by Lin-Xia Liu, Zhi-Kai Liao, Bing-Qi Dong, Shan Jiang, Tie-Chi Lei

    Liu LX, et al. Ann Dermatol. 2024 Apr;36:e30. https://doi.org/10.5021/ad.23.108


  • Preferences and perceptions of patients with metastatic castration-resistant prostate cancer for treatments and biomarker testing: An international qualitative study.

    by Robert J. Jones, Hannah Collacott, Alicia K. Morgans, Elena Castro, Stefan Machtens, Hiroji Uemura, Tommi Tervonen, Sameer Ghate, Shan Jiang, Theresa Cain, et al.

    63 Background: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease with significant morbidity. Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) are targeted therapeutics approved to treat mCRPC patients with genetic mutations in homologous recombination repair (HRR). However, to benefit from PARPi as a single agent, patients usually need to undergo biomarker testing to determine their mutation status. As an initial step to understand patient preferences for mCRPC treatments, this study investigated the treatment features important to mCRPC patients and their preferences for and perceptions of biomarker testing. Methods: This preliminary qualitative study included 25 men in the US, UK, Germany, Spain, and Japan with self-reported mCRPC diagnosed at least 6 months previously. Participants completed a 60-minute one-on-one interview about mCRPC treatments and disease impact. Results: Participants had a mean age of 62 years and were diagnosed with prostate cancer an average of 68 months prior. About half (52%) had metastasized > 1 year prior and more than half (56%) reported no HRR genetic mutation. The most frequently reported symptoms were pain (60%), urinary problems (56%), and fatigue (32%). Participants stated that pain impacted their sleep, daily activities, and social lives. 60% reported they shared treatment decision-making with their physician, some (24%) shared it with partners or caregivers, and others (32%) left treatment decisions up to their physician due to their lack of knowledge. Quality of life (QoL) was the most important treatment benefit reported (56%), followed by progression-free survival (PFS) (52%), overall survival (OS) (48%), and reduced pain (44%). Some participants reported their desire for prolonged survival needed to be balanced with adequate QoL. Few participants reported reduced fatigue (24%) or urinary problems (12%) as desired treatment benefits. 64% had previously undergone biomarker testing to determine mutation status. 56% of tested participants reported that their physician discussed the purpose and benefits of testing. Based on conversations with their physicians, both tested and untested participants felt that biomarker testing would inform them about heritable risk of mutation and help find new targeted treatments. Untested participants with a negative view of biomarker testing (22%) reported concerns about the need for further invasive biopsies. Conclusions: QoL followed by PFS, OS, and reduced pain were the most important benefits of treatment to participants. More than half of participants had a positive view of biomarker testing, especially if testing could lead to targeted therapies and inform about heritable risk. These results will inform the design of an international discrete choice study of biomarker testing among men with mCRPC.

  • Top Cited Papers
    Open Access

    Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

    by Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang

    Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. Trial registration: URL: https://www.clinicaltrials.gov/ . The unique identifier: ChiCTR2000029559.


  • Open Access

    Caution: The clinical characteristics of COVID-19 patients at admission are changing

    by Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Tao Wang, Zhengli Shi, Zhan Zhang

    Background: With the emergence of 4 rd generation transmission, the prevention and treatment of the novel coronavirus disease 2019 (COVID-19) has entered a new period. We aimed to report several changes in the clinical characteristics at admission of patients with COVID-19. Methods: Clinical records and laboratory results of patients suffering from COVID-19 were retrospectively reviewed and matched with the admission dates to analyze the changes in characteristics at the onset of illness. Results: Of the 89 affected patients, 31 [34.8%] patients were admitted from January 16 to 22, and 58 [65.2%] were admitted from January 23 to 29. Patients were admitted with more systemic symptoms, such as fever (21 [67.7%] of 31), fatigue (13 [41.9%] of 31), and myalgia (7 [22.6%] of 31), before January 23. More patients (10 [32.3%] of 31) admitted before January 23 had a small amount of sputum production compared with a smaller proportion (4 [6.9%] of 58) of the patients admitted after January 23. Other symptoms, such as cough, nausea, diarrhea, and chest tightness, were not significantly different between the two groups. In addition, the group admitted before January 23 had a larger proportion of patients with reduced lymphocyte (13 [54.2%] of 24), CD3 (11 [54.4%] of 21), and CD8 (9 [42.9%] of 21) counts and elevated serum amyloid A (SAA, 18 [75%] of 24). Conclusions: The initial symptoms of recently infected patients seem more insidious, indicating that the new coronavirus may gradually evolve into a virus similar to influenza and latent in asymptomatic carriers for a long time. Summary: Compared with the cases admitted earlier, more hidden initial symptoms and improved immune system disorders appeared in COVID-19 patients infected recently.


  • Open Access

    Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells

    by Yue Wei, Hong Zheng, Yu Jia, Naran Bao, Shan Jiang, Simona Colla, Carlos E Bueso-Ramos, Joseph D Khoury, Zachary S. Bohannan, Guillermo Garcia-Manero

    Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)aremyeloid neoplasms characterized by abnormal bone marrow hematopoiesis and increased risk of transformation to acute myelogenous leukemia (AML). Epigenetic dysregulation and inflammatory hyper-activation have been recognized as key molecular abnormalities in the bone marrow (BM) hematopoietic stem and progenitor cells (HSPC) of MDS and CMML, which implies that key modulators of epigenetic and inflammatory regulation play an important role in the pathophysiology of these diseases, which could also serve as effective therapeutic targets. We recently identified such a candidate molecule: the histone demethylase KDM6B (JMJD3). We demonstrated that KDM6B is significantly overexpressed in the BM HSPCs of patients with MDS and CMML, and the overexpression of KDM6B mediates aberrant epigenetic activation of innate immune/inflammatory signals and consequent differentiation skewing in BM HSPCs of MDS, which can be reversed by targeting KDM6B. Importantly, systematic analysis of the global transcriptomic and genomic data of patients indicates that, although KDM6B is overexpressed in MDS and CMML, genetic lesions in this gene are very rare, and higher KDM6B expression correlates with TET2 mutation. These results imply that constitutive expression of KDM6B potentially interacts with more common genetic lesions during the development of MDS and CMML. To further investigate the effects of KDM6B overexpression on hematopoiesis and its role in myeloid disorders, we developed a novel hematopoietic KDM6B transgenic (Tg) mouse model that overexpresses KDM6B under the control of the murine hematopoietic specific Vav promoter (Vav-KDM6B). Long-term monitoring of the peripheral blood counts of the mice indicates that, although younger Vav-KDM6B mice display only minor changes in whole white blood cells (WBC), monocytes, and platelets, aged KDM6B mice (>1 year old) have significant increases of WBC (by 22%, ppin vivo repopulating capacity assays as well as gene expression profiling, are being performed.